Skip to content

The Clinical Study on the Intervention of XifengTongluo Method in Early Neurological Function Fluctuation After Venous Thrombolysis for Acute Ischemic Stroke (AIS)

The Clinical Study on the InterveXifengTongluo Method in Early Neurological Function Fluctuation After Venous Thrombolysis for Acute Ischemic Stroke (AIS)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000251
Enrollment
Unknown
Registered
2025-02-13
Start date
2024-06-11
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Interventions

Control group:Oral administration of placebo for 14 days in addition to conventional Western medicine treatment.
Intervention group:Oral administration of XifengTongluo formula granules for 14 days in addition to conventional Western medicine treatment.

Sponsors

Dongfang Hospital Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) AIS patients who meet the indications for thrombolysis and have received intravenous thrombolysis; (2) Patients who meet the diagnostic criteria for the syndrome of "Liver Yang Rising and Wind Causing Obstruction Blood Stasis in the Brain Collaterals" in stroke; (3) Patients with no change in NIHSS score or an increase of =1 point in NIHSS score within 72 hours after thrombolysis; (4) GCS score =12; (5) 18 - 85 years; (6)Signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients who did not receive intravenous thrombolysis for various reasons; (2) Receive direct endovascular thrombectomy or subsequent endovascular bridging interventions; (3) Cerebral infarction due to cardiogenic causes; (4) With severe circulatory respiratory urinary or digestive system diseases or cancer; (5) With liver or kidney dysfunction with levels exceeding twice the normal value; (6) Pregnant or lactating women; (7) Patients with pre-existing mental disorders or severe aphasia agnosia or inability to communicate and who cannot cooperate with efficacy assessments; (8) Allergic to the herbal ingredients used in this study protocol; (9) Currently participating in other clinical trials; (10) Patients who cannot comply with the study protocol.

Design outcomes

Primary

MeasureTime frame
NIHSS score;

Secondary

MeasureTime frame
SSS score;mRS score;Traditional Chinese Medicine (TCM) syndrome score;ADL score;MoCA score;

Countries

China

Contacts

Public ContactXianglan Jin

Dongfang Hospital of Beijing University of Chinese Medicine

jxlan2001@126.com+86 10 6768 9749

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026